Jonathan Joseph Chipman

Jonathan Joseph Chipman, PhD

Languages spoken: English, Portuguese

Academic Information

Departments Primary - Population Health Sciences , Adjunct - Family & Preventive Medicine

Lab

Research Interests

  • Adaptive Monitoring Schemes
  • Randomization Inference
  • Covariate-Adjusted Randomization
  • Causal Inference

Visit Dr. Chipman's Lab Site

I am an Assistant Professor of Biostatistics within the Department of Population Health Sciences (since 2019), and serve as a member of the Cancer Biostatistics Shared Resource at the Huntsman Cancer Institute (HCI).

My academic journey began at Brigham Young University (BS, Statistical Science) and the University of Minnesota (MS, Biostatistics). I worked four years as an MS statistician at the Dana-Farber Cancer Institute under Drs. Giovanni Parmigiani (prediction risk modelling for the BRCA gene; BRCAPRO) and Meredith Regan (prostate screening and quality of life outcomes with Dr. Martin Sanda).

I earned my Ph.D. in Biostatistics at Vanderbilt University under Dr. Robert Greevy, gaining methodological expertise in designing randomized trials and collaborative expertise in analyzing small- and large-scale observational studies. I love the causal inference connection between randomized and non-randomized trials and considering the issues to causal inference that can arise.

In randomized trials, I advocate for adjusting randomization for covariates and using analytic strategies which carry as few modelling assumptions as possible. (Example: Rematching on-the-Fly: Sequential Matched Randomization and a Case for Covariate-Adjusted Randomization)

My scientific philosophy is open to Frequentist, Bayesian, Likelihood, or other inferential approaches though with attention to scientific relevance. That is, I value interval estimation and anchoring estimates on clinical context. (Example: Sequential monitoring using the Second Generation P-Value with Type I error controlled by monitoring frequency)

I married Danielle Duffy Chipman the month before joining the University of Utah. We have a son, Peter, who is playful and seems to share his dad’s love for sports and his parents love of music and the outdoors.

Research Statement

I am trained in the design and analysis of clinical trials and observational studies.

My students and I develop methods that increase a study’s efficiency and effectiveness. Our current emphasis is in developing covariate-adjusted randomization and sample-size adaptive monitoring methods.

These methods reduce on average the noise in estimating an effect, improve the ability to study key subgroups, and allow for following studies until drawing clinically meaningful conclusions regarding the strength of the true effect.

Education History

Doctoral Training Vanderbilt University
 PhD
University of Minnesota
 MS
Undergraduate Brigham Young University
 BS

Selected Publications

Journal Article

  1. Schlechter CR, Kuzmenko TV, Orleans B, Wirth J, Kaphingst KA, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Dinkins CP, Greene T, Zhang Y, Chipman JJ, Friedrichs M, Lam CY, Pierce JH, Borsato EP, Cornia RC, Stevens L, Martinez A, Bradshaw RL, Hess R, Fiol GD, Wetter DW (2024). Reach and Engagement With Population Health Management Interventions to Address COVID-19 Among Safety-Net Health Care Systems. Am J Public Health, 114(11), 1207-1211. (Read full article)
  2. Chipman JJ, Rosenberger WF, Sverdlov O, Uschner D (2024). Special Issue on Randomization Methods to Design and Analyze Trial Estimands, Adjust for Covariates, and Implement Efficient Designs. Statistics in Biopharmaceutical Research, 16(4), 403--404.
  3. Jo Y, Puri S, Haaland B, Coletta A, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley W (2024). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer.
  4. Chipman JJGreevy RAMayberry LSBlume JD (2024). Sequential Monitoring Using the Second Generation P-Value with Type I Error Controlled by Monitoring Frequency. Am Stat. (Read full article)
  5. Wu YP, Brady HL, Wankier AP, Tanguy WJ, Smith HJ, Brunsgaard EK, Chipman J, DeSantis S, Abildso C, Haaland B, Schlechter CR, Wetter DW, Tercyak KP (2024). Preliminary effects of a rural skin cancer prevention intervention for youths. Health Psychol, 43(5), 339-351. (Read full article)
  6. Dindinger-Hill K, Horns J, Ambrose J, Vehawn J, Choudry M, Hunt TC, Chipman J, Haaland B, Li J, Hanson HA, ONeil B (2024). Effect of Health Service Area on Primary Care Physician Provision of Low-Value Cancer Screening. Ann Intern Med, 177(5), 583-591. (Read full article)
  7. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC Cancer, 24(1), 493. (Read full article)
  8. Del Fiol G, Orleans B, Kuzmenko TV, Chipman J, Greene T, Martinez A, Wirth J, Meads R, Kaphingst KK, Gibson B, Kawamoto K, King AJ, Siaperas T, Hughes S, Pruhs A, Pariera Dinkins C, Lam CY, Pierce JH, Benson R, Borsato EP, Cornia R, Stevens L, Bradshaw RL, Schlechter CR, Wetter DW (2024). SCALE-UP II: protocol for a pragmatic randomised trial examining population health management interventions to increase the uptake of at-home COVID-19 testing in community health centres. BMJ Open, 14(3). (Read full article)
  9. Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, ONeil BB (2024). Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer Med, 13(5), e7058. (Read full article)
  10. Chipman JJ, Mayberry L, Greevy RA Jr (2023). Rematching on-the-fly: Sequential matched randomization and a case for covariate-adjusted randomization. Stat Med, 42(22), 3981-3995. (Read full article)
  11. Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, ONeil BB (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance. Urol Pract, 101097UPJ0000000000000461. (Read full article)
  12. Stump TK, Wetter DW, Kuzmenko T, Orleans B, Kolp L, Wirth J, Del Fiol G, Chipman J, Haaland B, Kaphingst KA, Hersh AL, Wu YP (2023). Preliminary Reach of an Information Technology Approach to Support COVID-19 Testing in Schools. Pediatrics, 152(Suppl 1). (Read full article)
  13. Stump TK, Fastner S, Jo Y, Chipman J, Haaland B, Nagelhout ES, Wankier AP, Lensink R, Zhu A, Parsons B, Grossman D, Wu YP (2023). Objectively-Assessed Ultraviolet Radiation Exposure and Sunburn Occurrence. Int J Environ Res Public Health, 20(7). (Read full article)
  14. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. (Read full article)
  15. Sverdlov O, Carter K, Hilgers RD, Everett CC, Berger VW, Luo YA, Chipman JJ, Ryeznik Y, Ross J, Knight R, Yamada K (2023). Which Randomization Methods Are Used Most Frequently in Clinical Trials? Results of a Survey by the Randomization Working Group. Stat Biopharm Res. (Read full article)
  16. Carter K, Scheffold AL, Renteria J, Berger VW, Luo YA, Chipman JJ, Sverdlov O (2023). Regulatory Guidance on Randomization and the Use of Randomization Tests in Clinical Trials: A Systematic Review. Stat Biopharm Res. (Read full article)
  17. Uschner D, Sverdlov O, Carter K, Chipman J, Kuznetsova O, Renteria J, Lane A, Barker C, Geller N, Proschan M, Posch M, Tarima S, Bretz F, Rosenberger WF (2023). Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. Stat Biopharm Res. (Read full article)
  18. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 27(10), e815-e818. (Read full article)
  19. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. (Read full article)
  20. Wu YP, Parsons B, Jo Y, Chipman J, Haaland B, Nagelhout ES, Carrington J, Wankier AP, Brady H, Grossman D (2022). Outdoor activities and sunburn among urban and rural families in a Western region of the US: Implications for skin cancer prevention. Prev Med Rep, 29, 101914. (Read full article)
  21. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B (2022). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clin Genitourin Cancer, 20(3), e233-e243. (Read full article)
  22. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280. (Read full article)
  23. Coletta AM, Playdon MC, Baron KG, Wei M, Kelley K, Vaklavas C, Beck A, Buys SS, Chipman J, Ulrich CM, Walker D, White S, Oza S, Zingg RW, Hansen PA (2021). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. PLoS One, 16(10), e0258135. (Read full article)
  24. Berger VW, Bour LJ, Carter K, Chipman JJ, Everett CC, Heussen N, Hewitt C, Hilgers RD, Luo YA, Renteria J, Ryeznik Y, Sverdlov O, Uschner D, Randomization Innovative Design Scientific Working Group (2021). A roadmap to using randomization in clinical trials. BMC Med Res Methodol, 21(1), 168. (Read full article)
  25. Casper AC, Parsons MW, Chipman J, Burt LM Jr, Suneja G, Maurer KA, Gaffney DK (2021). Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol, 162(2), 454-460. (Read full article)
  26. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656. (Read full article)
  27. Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, Miller FW, Rider LG (2019). Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. J Rheumatol, 47(7), 1011-1018. (Read full article)
  28. Chu PY, Hackstadt AJ, Chipman J, Griffin MR, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Roumie CL (2020). Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. Diabetes Care, 43(7), 1462-1470. (Read full article)
  29. Min JY, Hackstadt AJ, Griffin MR, Greevy RA Jr, Chipman J, Grijalva CG, Hung AM, Roumie CL (2019). Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death. Diabetes Obes Metab, 21(12), 2626-2634. (Read full article)
  30. Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Griffin MR (2019). Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. JAMA, 322, 1-11. (Read full article)
  31. Presley CA, Chipman J, Min JY, Grijalva CG, Greevy RA, Griffin MR, Roumie CL (2018). Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications. J Gerontol A Biol Sci Med Sci, 74(8), 1282-1288. (Read full article)
  32. Einstein D, Patil D, Chipman J, Regan M, Davis K, Crociani C, Wagner A, Sanda M, Chang P (2019). Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology, 127, 53-60. (Read full article)
  33. Min JY, Presley CA, Wharton J, Griffin MR, Greevy RA Jr, Hung AM, Chipman J, Grijalva CG, Hackstadt AJ, Roumie CL (2019). Accuracy of a composite event definition for hypoglycemia. Pharmacoepidemiol Drug Saf, 28(5), 625-631. (Read full article)
  34. Min JY, Griffin MR, Chipman J, Hackstadt AJ, Greevy RA, Grijalva CG, Hung AM, Roumie CL (2019). Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea. Diabet Med, 36(4), 482-490. (Read full article)
  35. Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ (2018). Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clin Genitourin Cancer, 17(1), 32-37. (Read full article)
  36. Presley CA, Min JY, Chipman J, Greevy RA, Grijalva CG, Griffin MR, Roumie CL (2018). Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration. BMJ Open, 8(3), e020455. (Read full article)
  37. Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P, PROST-QA Consortium (2018). Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Pract Radiat Oncol, 8(6), 445-451. (Read full article)
  38. Chipman J, Braun D (2017). Simpson's paradox in the integrated discrimination improvement. Stat Med, 36(28), 4468-4481. (Read full article)
  39. Pencina MJ, Chipman J, Steyerberg EW, Braun D, Fine JP, DAgostino RB Sr (2017). Authors' response to comments. Stat Med, 36(28), 4511-4513. (Read full article)
  40. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S (2017). Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncol, 3(8), 1085-1093. (Read full article)
  41. Mihalcik S, Chipman J, Sanda M, Kaplan I, Crociani C, Chang P, PROST-QA Consortium (2016). Predicting erectile function following radiation therapy for prostate cancer at the point of care. J Urol, 195(4), e150.
  42. Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G (2016). A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat, 155(2), 375-83. (Read full article)
  43. Mazzola E, Chipman J, Cheng SC, Parmigiani G (2014). Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev, 23(8), 1689-95. (Read full article)
  44. Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA (2014). Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer, 120(7), 1076-82. (Read full article)
  45. Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P (2014). Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol, 191(3), 638-45. (Read full article)
  46. Chipman J, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P (2013). Providing access to risk prediction tools via the HL7 XML-formatted risk web service. Breast Cancer Res Treat, 140(1), 187-93. (Read full article)
  47. Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G (2013). Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat, 139(2), 571-9. (Read full article)
  48. Kazer MW, Bailey DE Jr, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG (2013). Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. BJU Int, 111(3 Pt B), E84-91. (Read full article)
  49. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG (2011). Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol, 186(3), 865-72. (Read full article)
  50. Bigler ED, Abildskov TJ, Petrie JA, Johnson M, Lange N, Chipman J, Lu J, McMahon W, Lainhart JE (2010). Volumetric and voxel-based morphometry findings in autism subjects with and without macrocephaly. Dev Neuropsychol, 35(3), 278-95. (Read full article)

Review

  1. Dunston ER, Mulibea PB, Chipman J, Zickmund S, Oza S, Zingg RW, Hansen PA, Coletta AM (2022). Factors influencing engagement in hospital-based exercise oncology programs: A narrative review. [Review]. PM R. (Read full article)

Book Chapter

  1. Chipman J (2017). Restricted Randomization: Pros and Cautions. In Berger VW (Ed.), Randomization, Masking, and Allocation Concealment (pp. 51-60). CRC Press.

Other

  1. Yoshida, K and Bartel, A and Chipman, JJ and others (2020). tableone: Create ‘Table 1’ to Describe Baseline Characteristics. R package version 0.12. 0. 2020. https://CRAN.R-project.org/package=tableone.